Excited to be at #SITC2022. Join us at Session114 in Hall B2 to hear about work on MAITs and TAMs done at @TimGreten lab National Cancer Institute

⚡️Excited to share our latest review with @TimGreten @NCIResearchCtr and the driving force Firouzeh Korangy out now Nature Reviews Cancer🤩. Had so much fun writing this! Check it out if you'd like to learn more on ILCs and ILTCs in cancer: rdcu.be/damTA

New #JITC article: Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma bit.ly/42Rhdjl Sophia Stock

Researchers Florian Märkl, Reda Benmebarek at Universität München demonstrated the modularity and controllability of a combination of a CAR T cell with a synthetic agonistic receptor (SAR; the extracellular domain of EGFRvIII linked to conventional CAR [...] bit.ly/3OWaVej

The FEBS-@IUBMB-ENABLE conference is organized by and for young researchers. Want to find out more before registering? Check out this short yet fully descriptive video for our conference! Looking forward to seeing you in Cologne 🗓23-25 November febs-iubmb-enableconference.org🎬

🥳🥳🥳Couldn't be happier to see our study on mucosal-associated invariant T (MAIT) cells in HCC published today in Cell. Article: authors.elsevier.com/c/1hbwdL7PXmdKm Brief summary of this exciting collaborative work between @TimGreten lab and Claassen Lab below (1/11):

Join @TimGreten Lab at #SITC2023 for #neuroimmune and liver cancer research. Dr. Reda Benmebarek discusses Anti-VEGF and #immunotherapy at 510 pm PST and Dr. Kylynda C. Bauer, PhD discusses nerves at 610 (#988).

Had a blast at the recent Scientific Illustration Workshop with a crowd of young scientists from the T-OP european doctoral training network. 🌈🔬 t.ly/JD8My

Very honored to receive the International Liver Cancer Association (ILCA) Fellowship 2023 Award supporting our research on Liver Cancer! Immense gratitude for the great support and fantastic mentoring at @NCIResearchCtr with @TimGreten Thank you for this fantastic opportunity

Very grateful to have been awarded the Cholangiocarcinoma Foundation Fellowship 2024, which will undoubtedly bolster our research efforts aiming to improve treatment outcomes for CCA patients! This is made possible by the great support and fantastic mentoring at @NCIResearchCtr with @TimGreten

Dr. Katie Kelley & Dr. Tim Greten from have been awarded the 2024 CCF Innovation Grant, funded by the Bachrach Family Foundation. Their project aims to understand resistance in cholangiocarcinoma, potentially improving treatment outcomes. Learn more: curecca.link/Innovation.

Online now: Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME dlvr.it/TJYphZ

1/ Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12 📄 cell.com/immunity/fullt…